Translational Development Acquisition Corp.
Translational Development Acquisition Corp (TDAC) is a blank check company incorporated on April 19, 2022 in the Cayman Islands as an exempted company, formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, or similar business combination with one or more target businesses. TDAC does not generate operating revenue. It raises capital through an IPO and holds proceeds in a trust account managed by Continental Stock Transfer & Trust Company, pending completion of an initial business combination. The company has two officers as of the FY2025 10-K filing (filed March 30, 2026) and does not intend to employ full-time staff prior to closing a business combination. Its sponsor is TDAC Partners LLC, successor to Stone Capital Partners LLC. The company's leadership includes affiliates connected to biotech and investment platforms, suggesting an intended focus on life sciences or biopharmaceutical targets, though no target has been disclosed in the filing excerpts.
Products & Services
Blank check shell company. Primary instruments include founder shares, private placement warrants, and trust account interests. No commercial products or services are offered.
Revenue Model
TDAC generates no operating revenue. IPO proceeds are held in a trust account and are not available for operations. The company has access to up to approximately $1,000,000 from IPO proceeds outside the trust account for working capital and expenses.
Customers & Markets
No customers or commercial end markets. The company's intended end market, based on leadership affiliations disclosed in the FY2025 10-K, includes biotech and drug development sectors, but no acquisition target has been identified in the filing.
Geographic Exposure
Incorporated in the Cayman Islands. Listed on a U.S. exchange. No operating business with geographic revenue exposure as of the FY2025 10-K.
Source: SEC 10-K, filed 2026-03-30
Financial Snapshot
Loading...
